Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Cellectar Biosciences, Inc. (CLRB)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.6110-0.0453 (-6.90%)
At close: 04:00PM EST
0.6599 +0.05 (+8.00%)
After hours: 07:55PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.6563
Open0.6700
Bid0.6100 x 1000
Ask0.6599 x 900
Day's Range0.6083 - 0.6999
52 Week Range0.6000 - 2.9800
Volume535,649
Avg. Volume353,384
Market Cap32.216M
Beta (5Y Monthly)1.65
PE Ratio (TTM)N/A
EPS (TTM)-0.5930
Earnings DateFeb 28, 2022 - Mar 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.58
  • GlobeNewswire

    Cellectar’s Iopofosine I-131 Exhibits Signals of Efficacy in Phase I Study for Pediatric Brain and Solid Tumors

    FLORHAM PARK, N.J., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced that patients in a Phase 1 study of iopofosine I-131 (“iopofosine”) in children and adolescents with relapsed and refractory high grade gliomas (HGGs) and soft tissue sarcomas, exhibited positive changes in various tumor parameters

  • GlobeNewswire

    Cellectar Reports Financial Results for the Third Quarter 2021 and Provides a Corporate Update

    FLORHAM PARK, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of targeted drugs for the treatment of cancer, today announced financial results for the third quarter ended September 30, 2021 and provided a corporate update. Third Quarter and Recent Corporate Highlights Announced the completion of the Part A portion of a safety and tolerability study of iopofosine I-131 (iop

  • GlobeNewswire

    Cellectar Appoints Laurence Reilly, M.D., LL.M Interim Chief Medical Officer

    Successful track record of developing and advancing oncology clinical programs through regulatory approvalFLORHAM PARK, N.J., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of targeted drugs for the treatment of cancer, today announced Laurence Reilly, M.D., LL.M as its interim chief medical officer. Dr. Reilly will oversee the company’s clinical development programs and report

Advertisement
Advertisement